On July 10, InnoCare Pharma rose 5.07% in regular trading, trading at HKD 14.06/share, with turnover of approximately HKD 74.04 million.

On the news front, Hong Kong-listed innovative drug stocks rallied broadly, with notable gains across the sector including Remegen and InnoCare rising over 5%, WuXi AppTec and WuXi Biologics gaining over 4%, and Hengrui Medicine climbing over 3%, indicating significant capital inflows into the sector.

At the company level, InnoCare recently announced that its self-developed CDH17-targeting novel ADC drug ICP-B208 completed first patient dosing, officially entering the clinical stage. Based on the company's proprietary ADC technology platform, ICP-B208 is designed to precisely target tumor cells while minimizing off-target effects. Currently, no CDH17-targeted ADC drug has been approved globally, highlighting the pipeline's differentiated competitive advantage.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)